ClinicalTrials.gg
RecruitingNCT07513376INTerpath-014Updated Nov 16, 2026

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

A Phase 3 interventional study of Intismeran and Pembrolizumab coformulated with berahyaluronidase alfa in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 129 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 16, 2026First sites in Chile and Colombia36 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
876
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Planned enrollment
5th of 88
876 · median 149
Started
2026
with 2 others
Phase 3
38 of 91
9 open now
Primary completion
2034-08
later than 24 of 25 live
Registered
90th of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 5th largest by planned enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 in phase 3, reaches primary completion later than 24 of the 25 other live ones, and was the 90th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery.

People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer.

The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a histological diagnosis of pathological Stage I (tumor ≤4 cm) non-small cell lung cancer (NSCLC) per American Joint Committee on Cancer (AJCC) 9th Edition with at least 1of the following high-risk pathologic features as assessed locally: tumor size >2cm, visceral pleural invasion, lymphovascular invasion, or high-grade histology
  • Has undergone a complete surgical resection of the primary NSCLC
  • Has not received other prior treatment outside of definitive surgery (including but not limited to chemotherapy, immunotherapy, targeted therapy, or radiotherapy) for their current Stage I NSCLC
  • Has provided a tissue sample from recent surgery along with the required blood sample
  • (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has diagnosis of any 1 of the following: small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, neuroendocrine tumor with large cell components, sarcomatoid carcinoma, or two synchronous primary NSCLCs
  • Has any cardiovascular disease within 12 months before randomization, including a history of coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), valvular heart disease requiring surgical intervention, Class III-IV heart failure, unstable angina, myocardial infarction (MI), pulmonary hypertension, cardiovascular accident (CVA), or hemodynamically unstable cardiac arrhythmia
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has active disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic ) is allowed
  • Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has active infection requiring systemic therapy other than those permitted in protocol
  • Has history of stem cell/solid organ transplant
  • Participants who have not adequately recovered from major surgery or have ongoing surgical complications
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
876 participants (estimated)

Study arms

  • Experimental
    Arm A: Intismeran + Pembrolizumab with Berahyaluronidase Alfa

    Participants will receive intismeran 1 mg via intramuscular (IM) injection plus pembrolizumab coformulated with berahyaluronidase alfa 790 mg via subcutaneous (SC) injection.

    Biological: Intismeran · Biological: Pembrolizumab coformulated with berahyaluronidase alfa

  • Experimental
    Arm B: Intismeran

    Participants will receive intismeran 1 mg via IM injection.

    Biological: Intismeran

  • Placebo comparator
    Arm C: Placebo

    Participants will receive dose-matched placebo via IM injection.

    Other: Placebo

Interventions

  • BiologicalIntismeran

    IM injection

    Also known as: V940, mRNA-4157

  • BiologicalPembrolizumab coformulated with berahyaluronidase alfa

    SC injection

    Also known as: MK-3475A

  • OtherPlacebo

    IM injection

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C

    DFS is defined as the time from randomization to any recurrence (local, locoregional, regional, or distant) by BICR, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 98 months

Secondary outcomes

  1. DFS as Assessed by BICR

    DFS is defined as the time from randomization to any recurrence (local, locoregional, regional, or distant) by BICR, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 98 months

  2. Distant Metastasis-Free Survival (DMFS)

    DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis by BICR or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.

    Time frame: Up to approximately 111 months

  3. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 123 months

  4. Number Participants Who Experience an Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 144 months

  5. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 144 months

  6. Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

    EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in global health status/quality of life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented.

    Time frame: Baseline and up to approximately 36 months

  7. Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented.

    Time frame: Baseline and up to approximately 36 months

  8. Change From Baseline in Role Functioning (EORTC QLQ-C30 Items 6-7) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. A higher score indicates a worse level of role functioning. The change from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) combined score will be presented.

    Time frame: Baseline and up to approximately 36 months

07

Study locations

129 of 129 sites recruiting
  • UC Davis Comprehensive Cancer Center ( Site 3204)
    Sacramento, California 95817, United States
    Recruiting
    • Study Coordinator · Contact916-734-5959
  • University of Colorado Cancer Center ( Site 3268)
    Aurora, Colorado 80045, United States
    Recruiting
    • Study Coordinator · Contact720-848-0300
  • Smilow Cancer Center at Yale-New Haven ( Site 3253)
    New Haven, Connecticut 06511, United States
    Recruiting
    • Study Coordinator · Contact203-688-4242
  • UF Health Cancer Center ( Site 3257)
    Gainesville, Florida 32610, United States
    Recruiting
    • Study Coordinator · Contact352-273-8010
  • Illinois Cancer Care ( Site 7000)
    Peoria, Illinois 61615, United States
    Recruiting
    • Study Coordinator · Contact309-240-6040
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9509)
    Ypsilanti, Michigan 48197, United States
    Recruiting
    • Study Coordinator · Contact734-712-4950
  • Washington University School of Medicine ( Site 3279)
    St Louis, Missouri 63110, United States
    Recruiting
    • Study Coordinator · Contact314-362-5000
  • Billings Clinic ( Site 3255)
    Billings, Montana 59101, United States
    Recruiting
    • Study Coordinator · Contact406-435-7480
  • NHO Revive Research Institute, LLC ( Site 3218)
    Lincoln, Nebraska 68506, United States
    Recruiting
    • Study Coordinator · Contact402-484-4900
  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)
    Reno, Nevada 89502, United States
    Recruiting
    • Study Coordinator · Contact775-982-4000
  • New York Oncology Hematology, P.C. ( Site 9000)
    Albany, New York 12206, United States
    Recruiting
    • Study Coordinator · Contact518-489-0044
  • Memorial Sloan Kettering Cancer Center ( Site 3296)
    New York, New York 10021, United States
    Recruiting
    • Study Coordinator · Contact212-639-2000
  • SUNY Upstate Medical University ( Site 3270)
    Syracuse, New York 13210, United States
    Recruiting
    • Study Coordinator · Contact315-464-8237
  • White Plains Hospital ( Site 3213)
    White Plains, New York 10601, United States
    Recruiting
    • Study Coordinator · Contact914-849-7500
  • Charles George VA Medical Center ( Site 3233)
    Asheville, North Carolina 28805, United States
    Recruiting
    • Study Coordinator · Contact828-298-7911
  • UNC Lineberger Comprehensive Cancer Center ( Site 3250)
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Study Coordinator · Contact919-966-4432
  • WakeMed Raleigh Campus ( Site 3214)
    Raleigh, North Carolina 27610, United States
    Recruiting
    • Study Coordinator · Contact919-350-2873
  • Sanford Fargo Medical Center ( Site 3236)
    Fargo, North Dakota 58102, United States
    Recruiting
    • Study Coordinator · Contact701-234-7563
  • Altru Health System ( Site 3254)
    Grand Forks, North Dakota 58201, United States
    Recruiting
    • Study Coordinator · Contact701-780-5400
  • Perelman Center for Advanced Medicine ( Site 3205)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact267-275-3770
  • Sanford Cancer Center ( Site 3266)
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Study Coordinator · Contact605-312-3250
  • Avera Cancer Institute ( Site 3209)
    Sioux Falls, South Dakota 57105, United States
    Recruiting
    • Study Coordinator · Contact605-322-3000
  • The University of Tennessee Medical Center ( Site 3223)
    Knoxville, Tennessee 37920, United States
    Recruiting
    • Study Coordinator · Contact865-305-8780
  • University of Texas-MD Anderson Cancer Center ( Site 3283)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact713-792-6363
  • Hematology Oncology Associates of Fredericksburg ( Site 3275)
    Fredericksburg, Virginia 22408, United States
    Recruiting
    • Study Coordinator · Contact540-371-0079
  • Fred Hutchinson Cancer Center ( Site 3202)
    Seattle, Washington 98109, United States
    Recruiting
    • Study Coordinator · Contact206-606-4801
  • West Virginia University ( Site 3237)
    Morgantown, West Virginia 26506, United States
    Recruiting
    • Study Coordinator · Contact304-598-4500
  • Gundersen Health System ( Site 3200)
    La Crosse, Wisconsin 54601, United States
    Recruiting
    • Study Coordinator · Contact608-775-2385
  • Royal North Shore Hospital ( Site 0502)
    St Leonards, New South Wales 2065, Australia
    Recruiting
    • Study Coordinator · Contact+61299267111
  • Princess Alexandra Hospital ( Site 0503)
    Brisbane, Queensland 4102, Australia
    Recruiting
    • Study Coordinator · Contact0731762111
  • One Clinical Research ( Site 0501)
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Study Coordinator · Contact+61410565868
  • Hospital de Clínicas de Passo Fundo ( Site 3601)
    Pasos Fundo, Rio Grande do Sul 99010-260, Brazil
    Recruiting
    • Study Coordinator · Contact+5554981271411
  • Hospital Samaritano De Sao Paulo ( Site 3612)
    São Paulo, 01232-010, Brazil
    Recruiting
    • Study Coordinator · Contact551138215871
  • Hospital Sírio Libanês ( Site 3611)
    São Paulo, 01308-060, Brazil
    Recruiting
    • Study Coordinator · Contact+5511994125414
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506)
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
    • Study Coordinator · Contact905-387-9495
  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503)
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • Study Coordinator · Contact6135496666
  • The Ottawa Hospital Cancer Centre ( Site 2508)
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Study Coordinator · Contact613-722-7000
  • Centre Hospitalier de l'Université de Montréal ( Site 2501)
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
    • Study Coordinator · Contact5148908000x26832
  • Clínica MEDS La Dehesa ( Site 3708)
    Lo Barnechea, Region M. de Santiago 7691236, Chile
    Recruiting
    • Study Coordinator · Contact+56229015945
  • Centro de Oncología de Precisión ( Site 3706)
    Santiago, Region M. de Santiago 7500000, Chile
    Recruiting
    • Study Coordinator · Contact+56225189885
  • FALP-UIDO ( Site 3701)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56226062331
  • Bradfordhill-Clinical Area ( Site 3700)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56 229490970
  • ONCOCENTRO APYS-ACEREY ( Site 3704)
    Viña del Mar, Valparaiso 2520598, Chile
    Recruiting
    • Study Coordinator · Contact+56323320860
  • Bradford Hill Norte ( Site 3705)
    Antofagasta, 2520598, Chile
    Recruiting
    • Study Coordinator · Contact+5644232023631
  • Promotora Médica Las Américas S.A. ( Site 3800)
    Medellín, Antioquia 050021, Colombia
    Recruiting
    • Study Coordinator · Contact+570343421010
  • Clinica Somer ( Site 3802)
    Rionegro, Antioquia 054040, Colombia
    Recruiting
    • Study Coordinator · Contact+5746052626
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 3806)
    Bogotá, Bogota D.C. 110131, Colombia
    Recruiting
    • Study Coordinator · Contact+573219198898
  • Clínica Universitaria Colombia ( Site 3803)
    Bogotá, Bogota D.C. 111321, Colombia
    Recruiting
    • Study Coordinator · Contact+573016254437
  • Instituto Nacional De Cancerologia-Oncología Clínica ( Site 3804)
    Bogota, Cundinamarca 111151, Colombia
    Recruiting
    • Study Coordinator · Contact+573108658288
  • Instituto Médico de Alta Tecnología S.A.S - IMAT S.A.S ( Site 3801)
    Montería, Departamento de Córdoba 230002, Colombia
    Recruiting
    • Study Coordinator · Contact+576047862333
  • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 2605)
    Rennes, Brittany Region 35000, France
    Recruiting
    • Study Coordinator · Contact+33299283738
  • Hôpital Foch ( Site 2604)
    Suresnes, Hauts-de-Seine 92150, France
    Recruiting
    • Study Coordinator · Contact+33146252000
  • CHU GABRIEL MONTPIED ( Site 2608)
    Clermont-Ferrand, Puy-de-Dome 63000, France
    Recruiting
    • Study Coordinator · Contact+33473754440
  • Thoraxklinik-Heidelberg gGmbH ( Site 2703)
    Heidelberg, Baden-Wurttemberg 69126, Germany
    Recruiting
    • Study Coordinator · Contact+4962213960
  • Augusta-Kranken-Anstalt ( Site 2702)
    Bochum, North Rhine-Westphalia 44791, Germany
    Recruiting
    • Study Coordinator · Contact00492345172453
  • Universitätsmedizin Johannes Gutenberg Universität Mainz ( Site 2711)
    Mainz, Rhineland-Palatinate 55131, Germany
    Recruiting
    • Study Coordinator · Contact+496131175778
  • SRH Wald-Klinikum Gera ( Site 2700)
    Gera, Thuringia 07548, Germany
    Recruiting
    • Study Coordinator · Contact+493658280
  • Errikos Dunant Hospital Center ( Site 5004)
    Athens, Attica 115 26, Greece
    Recruiting
    • Study Coordinator · Contact+302107470960
  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 5001)
    Athens, Attica 115 27, Greece
    Recruiting
    • Study Coordinator · Contact+302107700220
  • University General Hospital ''Attikon'' - General Hospital of West Attica "H AGIA VARVARA" ( Site 5003)
    Athens, Attica 124 62, Greece
    Recruiting
    • Study Coordinator · Contact302105832549
  • European Interbalkan Medical Center-Oncology Department ( Site 5000)
    Thessaloniki, 570 01, Greece
    Recruiting
    • Study Coordinator · Contact+302310400213
  • Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 4401)
    Pécs, Baranya 7623, Hungary
    Recruiting
    • Study Coordinator · Contact+36 72 535890
  • Borsod-Abaúj-Zemplén Vármegyei Központi Kórház És Egyetemi Oktatókórház ( Site 4409)
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
    Recruiting
    • Study Coordinator · Contact+36304835188
  • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 4406)
    Kecskemét, Bács-Kiskun county 6000, Hungary
    Recruiting
    • Study Coordinator · Contact+3676516700/6719
  • Gyor- Moson- Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz ( Site 4404)
    Győr, Győr-Moson-Sopron 9024, Hungary
    Recruiting
    • Study Coordinator · Contact+36 96 507 900
  • Nograd Varmegyei Szent Lazar Korhaz ( Site 4410)
    Salgótarján, Nógrád megye 3100, Hungary
    Recruiting
    • Study Coordinator · Contact+3632522000
  • Reformatus Pulmonologiai Centrum ( Site 4403)
    Törökbálint, Pest County 2045, Hungary
    Recruiting
    • Study Coordinator · Contact+36 23 511 570
  • Országos Onkológiai Intézet ( Site 4405)
    Budapest, 1122, Hungary
    Recruiting
    • Study Coordinator · Contact+3612248600
  • Rambam Health Care Campus ( Site 3303)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact+97247772688
  • Shaare Zedek Medical Center ( Site 3301)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact+97226555999
  • Hadassah Medical Center ( Site 3305)
    Jerusalem, 9112001, Israel
    Recruiting
    • Study Coordinator · Contact+97226777333
  • Meir medical center ( Site 3306)
    Kfar Saba, 4428164, Israel
    Recruiting
    • Study Coordinator · Contact+97297472555
  • Rabin Medical Center ( Site 3304)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact972-3-9378086
  • Sheba Medical Center ( Site 3302)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact+97235307096
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 2804)
    Bergamo, Lombardy 24127, Italy
    Recruiting
    • Study Coordinator · Contact+390352673694
  • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 2800)
    Milan, Lombardy 20133, Italy
    Recruiting
    • Study Coordinator · Contact+390223903816
  • Azienda Ospedaliera Universitaria Careggi ( Site 2806)
    Florence, Tuscany 50134, Italy
    Recruiting
    • Study Coordinator · Contact00390557947298
  • AO Santa Maria della Misericordia ( Site 2809)
    Perugia, Umbria 06132, Italy
    Recruiting
    • Study Coordinator · Contact+390755782661
  • Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 2803)
    Novara, 28100, Italy
    Recruiting
    • Study Coordinator · Contact003903213732296
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 2801)
    Roma, 00168, Italy
    Recruiting
    • Study Coordinator · Contact+390630155202
  • Hospital of the University of Occupational and Environmental Health, Japan ( Site 5516)
    Kitakyushu, Fukuoka 807-8556, Japan
    Recruiting
    • Study Coordinator · Contact+81-93-603-1611
  • National Hospital Organization Kyushu Cancer Center ( Site 5517)
    Fukuoka, 811-1395, Japan
    Recruiting
    • Study Coordinator · Contact+81-92-541-3231
  • Fukushima Medical University Hospital ( Site 5501)
    Fukushima, 960-1295, Japan
    Recruiting
    • Study Coordinator · Contact+81-24-547-1111
  • Yamagata University Hospital ( Site 5500)
    Yamagata, 990-9585, Japan
    Recruiting
    • Study Coordinator · Contact+81-23-633-1122
  • Ziekenhuis St. Jansdal ( Site 4800)
    Harderwijk, Gelderland 3844 DG, Netherlands
    Recruiting
    • Study Coordinator · Contact+31341463742
  • Radboudumc ( Site 4806)
    Nijmegen, Gelderland 6525 GA, Netherlands
    Recruiting
    • Study Coordinator · Contact+31243610353
  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 4809)
    Amsterdam, North Holland 1066 CX, Netherlands
    Recruiting
    • Study Coordinator · Contact+31205129111
  • Elisabeth-TweeSteden Ziekenhuis ( Site 4801)
    Tilburg, North Holland 5022 GC, Netherlands
    Recruiting
    • Study Coordinator · Contact+31132213101
  • Isala, locatie Zwolle ( Site 4804)
    Zwolle, Overijssel 8025 AB, Netherlands
    Recruiting
    • Study Coordinator · Contact088-6243254
  • Frisius Medisch Centrum ( Site 4808)
    Leeuwarden, Provincie Friesland 8934 AD, Netherlands
    Recruiting
    • Study Coordinator · Contact+31503614679
  • Meander Medisch Centrum ( Site 4802)
    Amersfoort, Utrecht 3813 TZ, Netherlands
    Recruiting
    • Study Coordinator · Contact+31338507843
  • University Medical Center Groningen ( Site 4807)
    Groningen, 9713 GZ, Netherlands
    Recruiting
    • Study Coordinator · Contact+31503614679
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 4202)
    Poznan, Greater Poland Voivodeship 60-569, Poland
    Recruiting
    • Study Coordinator · Contact+48616654242
  • Instytut Gruzlicy i Chorob Pluc w Warszawie ( Site 4200)
    Warsaw, Masovian Voivodeship 01-138, Poland
    Recruiting
    • Study Coordinator · Contact+48224312360
  • IP Clinic ( Site 4204)
    Lodz, Łódź Voivodeship 90-752, Poland
    Recruiting
    • Study Coordinator · Contact+48 48 42 208 97 98
  • Wojewodzki Szpital Specjalistyczny im. sw. Rafala w Czerwonej Gorze ( Site 4206)
    Chęciny, Świętokrzyskie Voivodeship 26-060, Poland
    Recruiting
    • Study Coordinator · Contact+48413465545wew256
  • National Cancer Center ( Site 5202)
    Goyang-si, Kyonggi-do 10408, South Korea
    Recruiting
    • Study Coordinator · Contact+82-31-920-1676
  • Seoul National University Bundang Hospital ( Site 5200)
    Seongnam-si, Kyonggi-do 13620, South Korea
    Recruiting
    • Study Coordinator · Contact+82317877071
  • The Catholic University Of Korea St. Vincent's Hospital ( Site 5203)
    Suwon, Kyonggi-do 16247, South Korea
    Recruiting
    • Study Coordinator · Contact82-31-249-7744
  • Chungbuk National University Hospital ( Site 5201)
    Cheongju-si, North Chungcheong 28644, South Korea
    Recruiting
    • Study Coordinator · Contact+82432696015

Showing the first 100 of 129 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2034, 99 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 99 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 7, 2026
StartActual
May 4, 2026
Primary completionEst.
Aug 22, 2034
CompletionEst.
May 11, 2038
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
36 sites added — first sites in Chile and Colombia
Show 36 added (8 United States, 6 Chile, 6 Colombia, 3 Japan, 2 United Kingdom, 2 Italy, 2 Brazil, 2 Germany, 1 France, 1 Spain, 1 Canada, 1 Hungary, 1 South Korea)
  • Charing Cross Hospital ( Site 0407) · London, United Kingdom
  • Washington University School of Medicine ( Site 3279) · St Louis, United States
  • Clínica MEDS La Dehesa ( Site 3708) · Lo Barnechea, Chile
  • Centro de Oncología de Precisión ( Site 3706) · Santiago, Chile
  • Bradfordhill-Clinical Area ( Site 3700) · Santiago, Chile
  • ONCOCENTRO APYS-ACEREY ( Site 3704) · Viña del Mar, Chile
  • Bradford Hill Norte ( Site 3705) · Antofagasta, Chile
  • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 2605) · Rennes, France
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 2804) · Bergamo, Italy
  • AO Santa Maria della Misericordia ( Site 2809) · Perugia, Italy
  • Hospital General de Valencia ( Site 0304) · Valencia, Spain
  • UF Health Cancer Center ( Site 3257) · Gainesville, United States
  • Gundersen Health System ( Site 3200) · La Crosse, United States
  • Hospital de Clínicas de Passo Fundo ( Site 3601) · Pasos Fundo, Brazil
  • The Ottawa Hospital Cancer Centre ( Site 2508) · Ottawa, Canada
  • FALP-UIDO ( Site 3701) · Santiago, Chile
  • Promotora Médica Las Américas S.A. ( Site 3800) · Medellín, Colombia
  • Clinica Somer ( Site 3802) · Rionegro, Colombia
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 3806) · Bogotá, Colombia
  • Clínica Universitaria Colombia ( Site 3803) · Bogotá, Colombia
  • Instituto Nacional De Cancerologia-Oncología Clínica ( Site 3804) · Bogota, Colombia
  • Instituto Médico de Alta Tecnología S.A.S - IMAT S.A.S ( Site 3801) · Montería, Colombia
  • SRH Wald-Klinikum Gera ( Site 2700) · Gera, Germany
  • Hospital of the University of Occupational and Environmental Health, Japan ( Site 5516) · Kitakyushu, Japan
  • SUNY Upstate Medical University ( Site 3270) · Syracuse, United States
  • Yamagata University Hospital ( Site 5500) · Yamagata, Japan
  • University of Texas-MD Anderson Cancer Center ( Site 3283) · Houston, United States
  • Fred Hutchinson Cancer Center ( Site 3202) · Seattle, United States
  • Hospital Samaritano De Sao Paulo ( Site 3612) · São Paulo, Brazil
  • Gyor- Moson- Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz ( Site 4404) · Győr, Hungary
  • …and 6 more on the registry record
across 7 updates, Sep 28, 2026 – Nov 16, 2026
Show all 7 updates
  1. Nov 16, 2026
    3 sites added
    Show 3 added (2 United States, 1 Japan)
    • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9509) · Ypsilanti, United States
    • Memorial Sloan Kettering Cancer Center ( Site 3296) · New York, United States
    • National Hospital Organization Kyushu Cancer Center ( Site 5517) · Fukuoka, Japan
  2. Nov 9, 2026
    2 sites added
    Show 2 added (1 Germany, 1 South Korea)
    • Universitätsmedizin Johannes Gutenberg Universität Mainz ( Site 2711) · Mainz, Germany
    • Severance Hospital, Yonsei University Health System ( Site 5204) · Seoul, South Korea
    + 1 other change: verification date
  3. Oct 30, 2026
    5 sites added
    Show 5 added (2 United States, 1 Brazil, 1 Hungary, 1 United Kingdom)
    • University of Texas-MD Anderson Cancer Center ( Site 3283) · Houston, United States
    • Fred Hutchinson Cancer Center ( Site 3202) · Seattle, United States
    • Hospital Samaritano De Sao Paulo ( Site 3612) · São Paulo, Brazil
    • Gyor- Moson- Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz ( Site 4404) · Győr, Hungary
    • University College London Hospitals ( Site 0406) · London, United Kingdom
  4. Oct 19, 2026
    2 sites added
    Show 2 added (1 United States, 1 Japan)
    • SUNY Upstate Medical University ( Site 3270) · Syracuse, United States
    • Yamagata University Hospital ( Site 5500) · Yamagata, Japan
  5. Oct 9, 2026
    13 sites added — first site in Colombia
    Show 13 added (6 Colombia, 2 United States, 1 Brazil, 1 Canada, 1 Chile, 1 Germany, 1 Japan)
    • UF Health Cancer Center ( Site 3257) · Gainesville, United States
    • Gundersen Health System ( Site 3200) · La Crosse, United States
    • Hospital de Clínicas de Passo Fundo ( Site 3601) · Pasos Fundo, Brazil
    • The Ottawa Hospital Cancer Centre ( Site 2508) · Ottawa, Canada
    • FALP-UIDO ( Site 3701) · Santiago, Chile
    • Promotora Médica Las Américas S.A. ( Site 3800) · Medellín, Colombia
    • Clinica Somer ( Site 3802) · Rionegro, Colombia
    • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 3806) · Bogotá, Colombia
    • Clínica Universitaria Colombia ( Site 3803) · Bogotá, Colombia
    • Instituto Nacional De Cancerologia-Oncología Clínica ( Site 3804) · Bogota, Colombia
    • Instituto Médico de Alta Tecnología S.A.S - IMAT S.A.S ( Site 3801) · Montería, Colombia
    • SRH Wald-Klinikum Gera ( Site 2700) · Gera, Germany
    • Hospital of the University of Occupational and Environmental Health, Japan ( Site 5516) · Kitakyushu, Japan
    + 1 other change: verification date
  6. Oct 1, 2026
    10 sites added — first site in Chile
    Show 10 added (5 Chile, 2 Italy, 1 United States, 1 France, 1 Spain)
    • Washington University School of Medicine ( Site 3279) · St Louis, United States
    • Clínica MEDS La Dehesa ( Site 3708) · Lo Barnechea, Chile
    • Centro de Oncología de Precisión ( Site 3706) · Santiago, Chile
    • Bradfordhill-Clinical Area ( Site 3700) · Santiago, Chile
    • ONCOCENTRO APYS-ACEREY ( Site 3704) · Viña del Mar, Chile
    • Bradford Hill Norte ( Site 3705) · Antofagasta, Chile
    • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 2605) · Rennes, France
    • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 2804) · Bergamo, Italy
    • AO Santa Maria della Misericordia ( Site 2809) · Perugia, Italy
    • Hospital General de Valencia ( Site 0304) · Valencia, Spain
  7. Sep 28, 2026
    1 site added
    Show site
    • Charing Cross Hospital ( Site 0407) · London, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07513376
Collaborators
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
May 4, 2026
Primary completion
Aug 22, 2034 (estimated)
Completion
May 11, 2038 (estimated)
Last update
Nov 16, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Intismeran autogene

Start the discussion